Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.658 EUR | -12.62% | -8.61% | -91.92% |
Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
Sales 2023 | -3.62K -3.88K | Sales 2024 * | - | Capitalization | 19.63M 21.01M |
---|---|---|---|---|---|
Net income 2023 | -28M -29.97M | Net income 2024 * | -18M -19.27M | EV / Sales 2023 | -53,497 x |
Net cash position 2023 | 18.52M 19.83M | Net cash position 2024 * | 19.55M 20.93M | EV / Sales 2024 * | - |
P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.05
x | Employees | 15 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.56% |
Latest transcript on Vivoryon Therapeutics N.V.
1 day | -12.62% | ||
1 week | -8.61% | ||
Current month | +21.85% | ||
1 month | +25.57% | ||
3 months | -92.77% | ||
6 months | -91.43% | ||
Current year | -91.92% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 0.658 | -12.62% | 725 730 |
24-04-29 | 0.753 | -5.88% | 425,381 |
24-04-26 | 0.8 | -2.44% | 344,230 |
24-04-25 | 0.82 | -8.38% | 1,589,391 |
24-04-24 | 0.895 | +24.31% | 3,324,608 |
Real-time Euronext Amsterdam, April 30, 2024 at 10:11 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-91.92% | 21.03M | |
+1.41% | 42.86B | |
+11.69% | 42.74B | |
+45.09% | 41.36B | |
-8.83% | 27.68B | |
+7.57% | 25.15B | |
-22.96% | 18.63B | |
+29.69% | 12.37B | |
-2.44% | 11.92B | |
+7.60% | 11.21B |
- Stock Market
- Equities
- VVY Stock